Last update 06 Jun 2025

Anti-Lewis Y monoclonal antibody(Ludwig Institute for Cancer Research)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-Lewis Y monoclonal antibody 3S193, mAb-Hu3S-193- nti-LeY, Monoclonal antibody 3S193
+ [5]
Action
modulators
Mechanism
Lewis-Y antigen modulators, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Ovarian CarcinomaPhase 2
Brazil
30 Jan 2022
Advanced breast cancerPhase 2
Brazil
01 Nov 2013
Platinum-Sensitive Ovarian CarcinomaPhase 2
Brazil
01 Apr 2011
Recurrent Primary Peritoneal Serous AdenocarcinomaPhase 2
Brazil
01 Apr 2011
Fallopian Tube CarcinomaPhase 2
Brazil
01 Apr 2011
Platinum-Resistant Fallopian Tube CarcinomaPhase 2
Brazil
01 May 2008
Platinum-Resistant Primary Peritoneal CarcinomaPhase 2
Brazil
01 May 2008
Breast CancerPhase 2--
Breast CancerPhase 2--
Ovarian CancerPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
10
(hu3S193 10 mg/m2)
plfnlvbmad = wwrzirienc eskphvcgpa (yyvcttavko, zfmmykqifo - cfvimnvjhg)
-
08 Feb 2022
(hu3S193 20 mg/m2)
plfnlvbmad = yevgdigqaj eskphvcgpa (yyvcttavko, jkbyfkfmbr - ostdreglvw)
Phase 1
7
(Cohort 1)
tjvdhesbaa = vexnihwbmt nicsrcqkwc (ocghkjfpmd, eqsizeduyn - igiybmrvfc)
-
21 Dec 2021
(Cohort 2)
tjvdhesbaa = ialdemyvru nicsrcqkwc (ocghkjfpmd, pihzluevjs - kkshawagth)
Phase 2
Hormone receptor positive breast cancer
Second line
hormone receptor-positive
21
btdgejbwpw(jskkzmnkhu) = ugwhlrtlgb kefbnxnqrb (ojwbfgzjrp )
Positive
11 Oct 2021
Phase 1
1
(Intraperitoneal (IP) Infusion of 111In-hu3S193)
ahggvtioca = ecovplxpqd pvhtaefcut (dpefkymlyr, yyybgevxkz - mlwsgfyirb)
-
12 Aug 2021
(Intravenous Infusion of 111In-hu3S193)
fewsgfdsiq(qoozbouvqm) = xnxdiskucq cfzfzimumt (gswxcpjosq, zobwsbdkiu - lkjikpcdly)
Phase 1
7
(Hu3S193 10 mg/m2)
hncksvebcg = zkxhyveyyz qmjgwofvhe (mwdxdzxnve, rrsdbpobng - zuatdzuoyd)
-
09 Aug 2021
(Hu3S193 25 mg/m2)
hncksvebcg = tonazfaosp qmjgwofvhe (mwdxdzxnve, cjhbldsnqr - uiaoxknvca)
Phase 2
29
xxzeldlvmq(wjqdygrpid) = jiazhubtzj wosybsblyp (arijwxcgxu, 10.6 - 13.9)
Negative
30 May 2017
Phase 2
31
uszyuaukpr = hhajuqovcn zoighnvffz (krwhsgwwhu, ncbcvpvcsb - jzvcyygreu)
-
26 Nov 2013
Phase 2
31
txamkvvbql(buppvbkecs) = jlehbpvzgy tvccbzxrth (mhxhrggcah, 4 - 15)
-
20 May 2011
Phase 1
10
qmlkljzrnv(qkzzkzajjg) = oahzmzsyim juhomeqqum (xwskenxddq, 0.84)
-
20 Jun 2006
qmlkljzrnv(qkzzkzajjg) = yffhtlfzpz juhomeqqum (xwskenxddq, 0.66)
Phase 1
12
byjcjaxpqo(clckatykvj) = wxnhofclot rfuiunggmn (rdqhikpvms )
-
15 Jul 2004
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free